Research also needs to determine whether there are certain types of patients who would respond more favorably to pazopanib, Lu added.
"Can we identify a subgroup of patients who will have a good response and will have a prolonged period where they can be off of chemotherapy?" she said. "For all biologic agents, that's an important area of research, to identify markers that will tell us which patients will have that benefit."
For more on ovarian cancer, go to the U.S. National Cancer Institute.
Copyright © 2012 HealthDay. All rights reserved.